Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation | MicrobiomeTrials← Back to trialsNCT06905054
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-04-15Est. Completion: 2028-03-30
Enrollment target: 80 participants Locations- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Other microbiome trials you might be interested in
Primary Sclerosing Cholangitis
This study is a clinical trial being done to investigate the efficacy of drug BRS201 (hydroxocobalamin) as a treatment i…
Chestnut Hill, United StatesEst. completion May 1, 2027
Primary Sclerosing Cholangitis
Background:
Primary sclerosing cholangitis is a rare chronic liver disease. It affects the bile ducts of the
liver. It…
Bethesda, United StatesEst. completion Oct 31, 2026